Sciele Pharma has received FDA approval for all four dosage strengths of its new Sular (nisoldipine) formulation. The new Sular formulation uses SkyePharma’s Geomatrix technology to provide a lower dose of Sular for each of its current doses. Sular is indicated for the treatment of hypertension and may be used as monotherapy or in combination with other antihypertensive agents. The product is expected to be available during the first quarter of 2008.
For more information call (800) 849-9707 ext. 1454 or visit www.sciele.com.